Literature DB >> 22151484

The costs and benefits of deep brain stimulation surgery for patients with dystonia: an initial exploration.

John Yianni1, Alexander L Green, Emma McIntosh, Richard G Bittar, Carol Joint, Richard Scott, Ralph Gregory, Peter G Bain, Tipu Z Aziz.   

Abstract

Objectives.  To perform a preliminary cost-utility and cost-benefit of deep brain stimulation (DBS) in the treatment of dystonia, Materials and Methods.  We conducted a prospective study of 26 patients undergoing DBS for the treatment of dystonia. We performed a cost-utility analysis using the Euroquol (EQ-5D) questionnaire. A cost-benefit analysis used the willingness-to-pay principle and costs of treatment were calculated retrospectively in order to calculate the cost-benefit. Results.  We found that the EQ-5D score improved from 29 to 76.2 points after surgery, an incremental utility of 0.47. There was an overall gain of 0.94 quality-adjusted life-years (QALY) with a cost of £33,980 per QALY. Conclusions.  DBS for dystonia, while an expensive treatment, compares favorably to therapies that are commonly used for other conditions.

Entities:  

Year:  2005        PMID: 22151484     DOI: 10.1111/j.1525-1403.2005.05233.x

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  4 in total

1.  Treatment of focal dystonia.

Authors:  Amit Batla; Maria Stamelou; Kailash P Bhatia
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

Review 2.  Cost-Effectiveness of Deep Brain Stimulation With Movement Disorders: A Systematic Review.

Authors:  Tho Thi Hai Dang; David Rowell; Luke B Connelly
Journal:  Mov Disord Clin Pract       Date:  2019-05-17

3.  Autonomic neurosurgery: from microvascular decompression to image guided stimulation.

Authors:  Eac Pereira; Al Green
Journal:  Biomed Imaging Interv J       Date:  2007-01-01

Review 4.  Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies?

Authors:  James Buchanan; Sarah Wordsworth
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.